CLINICAL TRIALS PROFILE FOR PROMACTA
✉ Email this page to a colleague
All Clinical Trials for Promacta
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00643929 ↗ | LENS - Long-term Eltrombopag Observational Study | Completed | GlaxoSmithKline | 2007-02-01 | A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects. | |
NCT00909363 ↗ | Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients | Terminated | Novartis Pharmaceuticals | Phase 2 | 2009-06-01 | The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo. |
NCT00909363 ↗ | Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients | Terminated | Weill Medical College of Cornell University | Phase 2 | 2009-06-01 | The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Promacta
Condition Name
Clinical Trial Locations for Promacta
Trials by Country
Clinical Trial Progress for Promacta
Clinical Trial Phase
Clinical Trial Sponsors for Promacta
Sponsor Name